Solasia Pharma K.K. provided consolidated earnings guidance for the fiscal year ending December 31, 2023. For the year, the company expects revenue in the range of ¥1,000 million to ¥1,800 million, operating loss in the range of ¥1,150 million to ¥350 million, loss in the range of ¥1,150 million to ¥350 million, basic loss per share in the range of ¥6.85 to ¥2.08.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
28 JPY | +3.70% | +7.69% | -37.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.78% | 31.53M | |
-2.10% | 89.08B | |
+2.76% | 40.9B | |
-12.92% | 32.25B | |
+54.69% | 25.14B | |
-16.51% | 15.39B | |
-8.27% | 11.91B | |
-42.60% | 11.89B | |
-12.82% | 11.64B | |
+7.34% | 9.03B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023